Bio-Rad Tops Q2 Revenue, Launches $80–90M Restructuring, and Reaffirms 2026 Outlook
BIO sits 38% above its 52-week low of $236.73.
Summary
Bio-Rad posted Q2 2026 revenue of $651M, exceeding estimates, and announced an $80–90M restructuring plan to improve margins while reaffirming full-year guidance.
Key Events · Earnings and Guidance · BIO
-
Q2 Revenue Beats Consensus
Revenue came in at $651M, flat year-over-year but surpassing the $623.99M consensus by over 4%. Clinical Diagnostics grew 2.6%, while Life Science declined 4.1%.
-
Restructuring Plan Announced
A restructuring plan was initiated, with estimated pre-tax charges of $80–90 million covering headcount reductions and facility closures. Completion is expected substantially by the end of fiscal 2027.
-
Full-Year Outlook Reaffirmed
Management reaffirmed its 2026 guidance: a non-GAAP currency-neutral revenue decline of 3.0% to growth of 0.5%, and a non-GAAP operating margin of 10.0% to 12.0%.
-
GAAP Net Income Boosted by Sartorius Gain
GAAP net income reached $371.4M ($13.85 per diluted share), including a $458M non-cash gain from the change in fair value of the Sartorius investment. Non-GAAP net income was $70.2M ($2.62 per diluted share).
Analysis · BIO · Industrial Applications And Services
Second-quarter revenue of $651 million beat the consensus by over 4%, supported by clinical diagnostics growth while life sciences remained soft. Alongside the results, management unveiled a restructuring plan carrying $80–90 million in charges, aimed at lifting operating performance. The full-year outlook was reaffirmed, providing a steady backdrop. GAAP net income was heavily influenced by a non-cash gain from the Sartorius investment, but non-GAAP earnings were essentially flat year-over-year. The restructuring signals a clear focus on margin expansion in a mixed demand environment, and the reaffirmed guidance adds stability. With the stock trading near its 52-week high, the market had already priced in some optimism, but the restructuring introduces a new cost-cutting narrative.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIO was trading at $326.33 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $236.73 to $343.12. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.